News

Money Talks News on MSN1d
Don't Ignore These Early Signs of a Progressive Liver Condition
A progressive liver condition affects thousands of Americans, but early symptoms are often dismissed as everyday ailments. Learn the critical warning signs of Primary biliary cholangitis (PBC) and ...
Gastroenterology Advisor1d
Primary Biliary Cholangitis Rates Increasing in Western Pacific
The global prevalence of primary biliary cholangitis (PBC) has increased, particularly in the Western Pacific region of the world, according to study results published in Clinical Gastroenterology and ...
Pharmabiz2d
EMA accepts GSK’s MAA for linerixibat for cholestatic pruritus in patients with primary biliary cholangitis
EMA accepts GSK’s MAA for linerixibat for cholestatic pruritus in patients with primary biliary cholangitis: London, UK Tuesday, June 24, 2025, 09:00 Hrs [IST] GSK plc announced ...
pharmaphorum3d
EU kicks off review of GSK's linerixibat in PBC
The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...
EMA accepts marketing authorisation application for GSK's linerixibat
GSK said on Monday that the European Medicines Agency has accepted its marketing authorisation application for linerixibat, an investigational treatment for cholestatic pruritus in patients with ...
Lisa thought her itch was just an allergy. In fact it was a common liver problem that mostly strikes women, often goes undetected for years and causes catastrophic da…
Lisa Woodcock's initial instinct when she first developed severe itching all over her body was to blame an allergic reaction ...
Dermatology Advisor9d
Linerixibat Under Review for Cholestatic Pruritus in PBC Patients
The FDA has accepted for review the NDA for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.
Managed Healthcare Executive13d
Case Study Uncovers Potential Autoimmune Link Between Hemophilia A and Primary Biliary Cholangitis
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...
BioWorld14d
Morphic Therapeutic describes new integrin αvβ1 antagonists
Morphic Therapeutic Inc. has identified compounds acting as integrin αvβ1 antagonists reported to be useful for the treatment of cancer, chronic kidney disease, diabetic nephropathy, pulmonary ...
Yahoo Finance22d
$2.27 Bn Primary Biliary Cholangitis Market Forecasts and Strategies to 2034: Strategic Partnerships Driving Innovations in Treatment, Growing Role of Combination Therapy in ...
The global primary biliary cholangitis market reached a value of nearly $979.47 million in 2024, having grown at a compound annual growth rate (CAGR) of 5.96% since 2019.
Yahoo Finance22d
$2.27 Bn Primary Biliary Cholangitis Market Forecasts and Strategies to 2034: Strategic Partnerships Driving Innovations in Treatment, Growing Role of Combination Therapy in ...
Primary Biliary Cholangitis Market. Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Primary Biliary Cholangitis Market Opportunities and Strategies to 2034" report has been added to ...
Pharm Exec1mon
Gilead’s Livdelzi Shows Lasting Efficacy in Primary Biliary Cholangitis, Regardless of Prior Therapy
Results from an interim analysis of the Phase III ASSURE trial found that Gilead’s Livdelzi (seladelpar) demonstrated sustained efficacy and a favorable safety profile in patients with primary biliary ...